A clinical study of DST-5407 for non-squamous non-small cell lung cancer
Latest Information Update: 06 Dec 2023
Price :
$35 *
At a glance
- Drugs DST-5407 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 30 Sep 2020 New trial record
- 24 Sep 2020 According to a DisperSol Technologies media release, the company expect to initiate this study in 2021.